Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15765878 | 0.94 | MGLL (0.43) | MGLLALDH1A1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL15758264 | 0.77 | MGLL (0.45) | MGLLALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL13543380 | 0.77 | MGLL (0.47) | MGLLALDH1A1HTTLMNANPSR1 | |
| SCHEMBL20513005 | 0.75 | MGLL (0.47) | MGLLALDH1A1HTTLMNANPSR1 | |
| SCHEMBL16754179 | 0.74 | MGLL (0.42) | MGLLALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL20850011 | 0.73 | MGLL (0.40) | MGLLHTTSMN1; SMN2 | |
| SCHEMBL20850022 | 0.73 | MGLL (0.40) | MGLLALDH1A1HTTSMN1; SMN2AKT1 | |
| SCHEMBL13226854 | 0.72 | MGLL (0.42) | MGLLHTTLMNASMN1; SMN2 | |
| SCHEMBL13226858 | 0.72 | MGLL (0.42) | MGLLHTTSMN1; SMN2ADORA1 | |
| SCHEMBL13668049 | 0.72 | MGLL (0.39) | MGLLALDH1A1HTTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150998-A1 | METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150998-A1 | METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES | PTMS, CRYAA, KRTCAP2 | MGLL 4294/4885ALDH1A1 1155/4885HTT 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.